Treatment of elderly patients with acute myeloid leukemia adjusted for performance status and presence of comorbidities: a Polish Adult Leukemia Group study

References

• Hiddemann W, Kern W, Schoch C. et al. Management of acute myeloid leukemia in elderly patients. J Clin Oncol 1999;17:3569–3576.
   PubMed Web of Science ®Google Scholar
• Lowenberg B, Zittoun R, Kerkhofs H, et al. On the value of intensive remission-induction chemotherapy in elderly patients of 65 + years with acute myeloid leukemia: a randomized phase III of the European Organization for Research and Treatment of Cancer Leukemia Group. J Clin Oncol 1989;7:1268–1274.
   PubMed Web of Science ®Google Scholar
• Menzin J, Lang K, Earle CC, et al. The outcomes and costs of acute myeloid leukemia among the elderly. Arch Intern Med 2002;162: 1597–1603.
   PubMed Web of Science ®Google Scholar
• Baz R, Rodriguez C, Fu AZ, et al.Impact of remission induction chemotherapy on survival in older adults with acute myeloid leukemia. Cancer 2007;110:1752–1729.
   PubMed Web of Science ®Google Scholar
• Wheatley K, Brookes CL, Howman A, et al. Prognostic factor analysis of the survival of elderly patients with AML in the MRC AML11 and LRF AML14 trials. Br J Haematol 2009;145:598–605.
   PubMed Web of Science ®Google Scholar
• Juliusson G, Antunovic P, Derolf A, et al. Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry. Blood 2009;113:4179–4187.
   PubMed Web of Science ®Google Scholar
• Goldstone AH, Burnett AK, Wheatley K, et al. Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML11 trial. Blood 2001;98:1302–1311.
   PubMed Web of Science ®Google Scholar
• Mengis C, Aebi S, Tobler A, et al. Assessment of differences in patients populations selected for excluded from participation in clinical phase III acute myelogenous leukemia trials. J Clin Oncol 2003;21:3933–3939.
   PubMed Web of Science ®Google Scholar
• Kantarjian H, O’Brien S, Cortes J, et al. Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcome. Cancer 2006;106:1090–1098.
   PubMed Web of Science ®Google Scholar
• Leith CP, Kopecky KJ, Godwin J, et al. Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study. Blood 1997;89:3323–3329.
   PubMed Web of Science ®Google Scholar
• Vey N, Coso D, Bardou VJ, et al. The benefit of induction chemotherapy in patients age ≥ 75 years. Cancer 2004;101:325–331.
   PubMed Web of Science ®Google Scholar
• Oran B, Weisdorf DJ. Survival for older patients with acute myeloid leukemia: a population-based study. Haematologica 2012; 97:1916–1924.
   PubMed Web of Science ®Google Scholar
• Howlader N, Noone AM, Krapcho M, et al., editors. SEER Cancer Statistics Review, 1975–2008, National Cancer Institute. Based on November 2010 SEER data submission. Bethesda, MD: NCI. Available from: http://seer.cancer.gov/csr/1975_2008/
   Google Scholar
• Hutchins LF, Unger JM, Crowley JJ, et al. Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med 1999;341:2061–2067.
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Ravandi F, O’Brien S, et al. Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia. Blood 2010;116:4422–4429.
   PubMed Web of Science ®Google Scholar
• Chen CC, Yang CF, Yang MH, et al. Pretreatment prognostic factors and treatment outcome in elderly patients with de novo acute myeloid leukemia. Ann Oncol 2005;16:1366–1373.
   PubMed Web of Science ®Google Scholar
• Appelbaum FR, Gundacker H, Head DR, et al. Age and acute myeloid leukemia. Blood 2006;107:3481–3485.
   PubMed Web of Science ®Google Scholar
• Etienne A, Esterni B, Charbonnier A, et al. Comorbidity is an independent predictor of complete remission in elderly patients receiving induction chemotherapy for acute myeloid leukemia. Cancer 2007;109:1376–1383.
   PubMed Web of Science ®Google Scholar
• Büchner T, Berdel WE, Haferlach C, et al. Age-related risk profile and chemotherapy dose response in acute myeloid leukemia: a study by the German Acute Myeloid Leukemia Cooperative Group. J Clin Oncol 2009;27:61–69.
   PubMed Web of Science ®Google Scholar
• Wahlin A, Billström R, Björ O, et al. Results of risk-adapted therapy in acute myeloid leukemia. A long-term population-based follow-up study. Eur J Haematol 2009;83:99–107.
   PubMed Web of Science ®Google Scholar
• Sorror ML, Maris MB, Storer B, et al. Comparing morbidity and mortality of HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative and myeloablative conditioning: influence of pretransplantation comorbidities. Blood 2004;104:961–968.
   PubMed Web of Science ®Google Scholar
• Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies development and validation. J Chron Dis 1987;40:373–383.
   PubMedGoogle Scholar
• Holowiecki J, Grosicki S, Robak T, et al. Addition of cladribine to daunorubicin and cytarabine increases complete remission rate after a single course of induction treatment in acute myeloid leukemia. Multicenter, phase III study. Leukemia 2004;18:989–997.
   PubMed Web of Science ®Google Scholar
• Cheson BD, Bennett JM, Kopecky KJ, et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol 2003;21:4642–4649.
   PubMed Web of Science ®Google Scholar
• Deschler B, de Witte T, Martelsmann R, et al. Treatment decision-making for older patients with high-risk myelodysplastic syndrome or acute myeloid leukemia: problems and approaches. Haematologica 2006;91:1513–1522.
   PubMed Web of Science ®Google Scholar
• Malfuson JV, Etienne A, Turlure P, et al. Risk factors and decision criteria for intensive chemotherapy in older patients with acute myeloid leukemia. Haematologica 2008;93:1806–1813.
   PubMed Web of Science ®Google Scholar
• Zaheer W, Hashmi A, Lichtman SM, et al. Effect of comorbidity and age on survival in 73 patients with de novo acute leukemia. Proc Am Soc Clin Oncol 1995:498.
   Google Scholar
• Sorror ML, Maris MB, Storb R, et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 2005;106:2912–2919.
   PubMed Web of Science ®Google Scholar
• Seferyńska I, Warzocha K. The Polish Register of Adult Acute Leukemias. Paper presented at Annual Meeting of Polish Adult Leukemia Group, 23 May 2008, Katowice, Poland.
   Google Scholar
• Kulik TB, Janiszewska M, Piróg E, et al. Health situation of the elderly in Poland and other European countries. Medycyna Ogólna i Nauki o Zdrowiu 2011;17:90–95.
   Google Scholar
• Farag SS, Archer KJ, Mrózek K, et al. Pretreatment cytogenetics add to other prognostic factors predicting complete remission and long-term outcome in patients 60 years of age or older with acute myeloid leukemia: results from Cancer and Leukemia Group B 8461. Blood 2006;108:63–73.
   PubMed Web of Science ®Google Scholar
• Röllig C, Thiede C, Gramatzki M, et al. A novel prognostic model in elderly patients with acute myeloid leukemia: results of 909 patients entered into the prospective AML96 trial. Blood 2010; 116:971–978.
   PubMed Web of Science ®Google Scholar
• Gupta V, Chun K, Yi QL, et al. Disease biology rather than age is the most important determinant of survival of patients ≥ 60 years with acute myeloid leukemia treated with uniform intensive therapy. Cancer 2005;103:2082–2090.
   PubMed Web of Science ®Google Scholar
• Rowe JM, Neuberg D, Friedenberg W, et al. A phase 3 study of three induction regimens and of priming with GM-CSF in older adults with acute myeloid leukemia: a trial by the Eastern Cooperative Oncology Group. Blood 2004;103:479–485.
   PubMed Web of Science ®Google Scholar
• Estey EH. Older adults: should the paradigm shift from standard therapy? Best Pract Res Clin Haematol 2008;21:61–66.
   PubMed Web of Science ®Google Scholar
• Sekeres MA, Elson P, Kalaycio ME, et al. Time from diagnosis to treatment initiation predicts survival in younger, but not older, acute myeloid leukemia patients. Blood 2009;113:28–36.
   PubMed Web of Science ®Google Scholar
• Grimwade D, Walker H, Harrison G, et al. The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial. Blood 2001;98:1312–1320.
   PubMed Web of Science ®Google Scholar
• Fröhling S, Schlenk RF, Kayser S, et al. German-Austrian AML Study Group. Cytogenetics and age are major determinants of outcome in intensively treated acute myeloid leukemia patients older than 60 years: results from AMLSG trial AML HD98-B. Blood 2006;108: 3280–3288.
   PubMed Web of Science ®Google Scholar
• Estey E. Acute myeloid leukemia and myelodysplastic syndromes in older patients. J Clin Oncol 2007;25:1908–1915.
   PubMed Web of Science ®Google Scholar
• DeLima M, Ghaddar H, Pierce S, et al. Treatment of newly-diagnosed acute myelogenous leukaemia in patients aged 80 years and above. Br J Haematol 1996;93:89–95.
   PubMed Web of Science ®Google Scholar
• Ferrara F, Mirto S, Zagonel V, et al. Acute myeloid leukemia in the elderly: a critical review of therapeutic approaches and appraisal of results of therapy. Leuk Lymphoma 1998;29:375–382.
   PubMed Web of Science ®Google Scholar
• Burnett AK, Milligan D, Prentice AG, et al. A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment. Cancer 2007;109:1114–1124.
   PubMed Web of Science ®Google Scholar
• O’Donnell MR, Appelbaum FR, Baer MR, et al. Acute myeloid leukemia clinical practice guidelines in oncology. J Natl Compr Cancer Netw 2006;4:16–36.
   PubMedGoogle Scholar
• Morra E, Barosi G, Bosi A, et al. Clinical management of primary non-acute promyelocytic leukemia acute myeloid leukemia: Practice Guidelines by the Italian Society of Hematology, the Italian Society of Experimental Hematology, and the Italian Group for Bone Marrow Transplantation. Haematologica 2009;94:102–112.
   PubMed Web of Science ®Google Scholar